Table 2.
Prevalence of MetS and its components among the study participants and by gender: representative sample of Tunisian adults aged 35–74 years, Transition and Health Impact in North Africa (TAHINA) project, 2004–2005
| All participants (n 4654) | Men (n 1840) | Women (n 2814) | ||||
|---|---|---|---|---|---|---|
| % | 95 % CI | % | 95 % CI | % | 95 % CI | |
| Component of MetS | ||||||
| High WC | 47·7 | 46·3, 49·2 | 20·6 | 18·7, 22·4 | 65·5*** | 63·7, 67·2 |
| High BP | 49·6 | 48·2, 51·0 | 47·6 | 45·3, 49·9 | 50·9* | 49·0, 52·7 |
| High FBG | 14·0 | 13·0, 15·0 | 15·2 | 13·6, 16·9 | 13·1* | 11·9, 14·4 |
| High TC | 19·9 | 18·7, 21·0 | 16·1 | 14·4, 17·8 | 22·4*** | 20·8, 23·9 |
| High TAG | 54·1 | 52·7, 55·6 | 56·6 | 54·4, 58·9 | 52·5* | 50·6, 54·3 |
| MetS (NCEP-ATPIII definition) | 30·0 | 28·6, 31·3 | 20·6 | 18·7, 22·4 | 36·1*** | 34·3, 37·9 |
MetS, metabolic syndrome; WC, waist circumference; BP, blood pressure; FBG, fasting blood glucose; TC, total cholesterol; NCEP-ATPIII, National Cholesterol Education Program, Adult Treatment Panel III.
Values were significantly different from those in men: *P < 0·05, ***P < 0·001.